Aethlon Medical Receives Second Ethics Committee Approval for Hemopurifier Cancer Trial

Aethlon Medical Receives Second Ethics Committee Approval for Hemopurifier Cancer Trial

By, Admin 14 August 2024

Overview

Aethlon Medical, Inc., a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, announced that, on August 6, 2024, the Bellberry Human Research Ethics Committee (BHREC) granted full ethics approval to the Pindara Private Hospital for a safety, feasibility and dose-finding clinical trial of the Hemopurifier in patients with solid tumours who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Merck's Keytruda (pembrolizumab) or Bristol Myers Squibb's Opdivo (nivolumab) (AEMD-2022-06 Hemopurifier Study). The approval is valid for one year, until August 6, 2025. The trial will be conducted by Dr. Marco Matos and his staff at the Pindara Private Hospital, located in Queensland, Australia.

Words from CMO: Aethlon Medical

  • We are quite pleased that the BHREC accepted our responses to their thoughtful questions during their review and determined that our study meets the requirements of the National Statement application. Dr. Matos and his research team have a proven track record of enrollment in device trials in oncology patients that provides momentum to these trials,"" stated Steven LaRosa, MD, chief medical officer of Aethlon Medical. 
  • This is the second ethics committee approval we have received for our oncology trial in Australia after receiving approval from the ethics committee for Royal Adelaide Hospital in June.
  • Dr. LaRosa continued, ""The next step is to receive approval from the Research Governance Office at each hospital which reviews indemnities and insurance. Once these approvals are obtained, Aethlon, in concert with our Australian contract research organization, ReSQ, will conduct Site Initiation Visits (SIVs), after which patient enrollment may proceed.

The Effective Aethlon Hemopurifier

  • Currently, only approximately 30% of cancer patients who receive pembrolizumab or nivolumab treatment for solid tumours will have lasting clinical responses to these agents. 
  • Extracellular vesicles (EVs) produced by tumours have been implicated in resistance to anti-PD-1 therapies as well as the spread of cancers. 
  • The Aethlon Hemopurifier has been designed to bind and remove these EVs from the bloodstream, which may improve therapeutic response rates to anti-PD-1 antibodies. 
  • In preclinical studies, the Hemopurifier has been shown to reduce the number of exosomes in cancer patient plasma samples.

Primary and Other Outcomes

  • The primary endpoint of the approximate nine to 18-patient, safety, feasibility and dose-finding trial is safety. 
  • The trial will monitor any adverse events and clinically significant changes in lab tests of Hemopurifier treated patients with solid tumours with stable or progressive disease at different treatment intervals, after a two-month run in period of PD-1 antibody, Keytruda or Opdivo monotherapy. 
  • Patients who do not respond to the PD-1 therapy will be eligible to enter the Hemopurifier period of the study, where sequential cohorts will receive 1, 2 or 3 Hemopurifier treatments during a one-week period. 
  • In addition to monitoring safety, the study is designed to examine the number of Hemopurifier treatments needed to decrease the concentration of EVs and if these changes in EV concentrations improve the body's own natural ability to attack tumour cells. 
  • These exploratory central laboratory analyses are expected to inform the design of a subsequent efficacy and safety, Premarket Approval (PMA), study required by regulatory agencies.

About Aethlon Medical

  • Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!